SIGA Technologies, Inc. (SIGA) AI Stock Analysis

SIGA Technologies, Inc. is a New York-based pharmaceutical company founded in 1995 that specializes in the health security and infectious disease sectors. Its flagship product is TPOXX, an oral antiviral drug developed specifically to treat human smallpox caused by the variola virus. In addition to TPOXX, the company maintains a strategic partnership with Cipla Therapeutics to develop and broaden access to antibacterial medications designed to counter biothreats. With 49 employees, SIGA focuses on advancing pharmaceutical solutions tailored to critical biodefense and public health security needs.

SIGA's financial results show variability tied to procurement cycles, with a 5-year revenue CAGR of -5.4% from FY2020 to FY2025. Annual revenue decreased from $133.7M in FY2021 to $110.8M in FY2022, rose to $139.9M in FY2023, and held steady at $138.7M in FY2024 before dropping 31.8% to $94.6M in FY2025. Gross margin compressed from 87.6% in FY2021 to 68.6% in FY2025, while net income fell from $69.5M to $23.3M over the same timeframe. In the trailing twelve months, revenue reached $53.7M with a net loss per share of -$0.04. In the latest quarter ended June 30, 2026, quarterly revenue fell 49.5% and quarterly earnings fell 65.3% year-over-year.

As of June 30, 2026, SIGA held $117.6M in cash and short-term investments against total debt of $439,397, resulting in a net cash position of $117.1M. The company reported shareholders' equity of $165.3M, total assets of $175.7M, a current ratio of 21.72, and a debt-to-equity ratio of 0.00. In FY2025, operating cash flow stood at $43.5M and free cash flow was $43.1M. Capital allocation in FY2025 included $355,009 in capital expenditures, $433,763 in share buybacks, and $43.1M in dividends paid.

At a share price of $3.17, SIGA has a market capitalization of $227.8M and an enterprise value of $111.3M. The stock trades at a forward P/E of 2.9x and an EV/EBITDA of 3.7x, both well below the median of its US-listed Healthcare peers of 17.3x and 12.0x, respectively. Its price-to-sales multiple of 4.2x is close to the peer median of 4.1x. Over the past year, SIGA shares declined 57.1%, trailing the S&P 500 (SPY) return of 16.8%, and over five years the stock fell 31.2% compared to an 83.0% gain for the benchmark.

Wall Street coverage includes a mean price target of $17.53, representing an upside of 453.0% over the last close of $3.17. For the fiscal year ending December 31, 2026, the consensus EPS estimate is $0.05 on projected revenue of $59.9M, indicating an EPS decline of 84.4%. For the following fiscal year, 1 analyst projects revenue of $162.1M and EPS of $1.08, representing projected growth of 170.7% and 2060.0%, respectively. Over the trailing four quarters, SIGA has topped EPS estimates once, with its next earnings release scheduled for November 5, 2026.

This page is an AI-written research summary of SIGA Technologies, Inc. (SIGA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: SIGA income statement, SIGA balance sheet, SIGA key metrics, SIGA analyst forecast, SIGA chart. See the SIGA stock overview for the latest quote and news.